JUN 1 7 2009 Subst. for form 1449/PTO

TA TRADEMANT INFORMATION DISCLOSURE STATEMENT **BY APPLICANT**

of

(Use as many sheets as necessary)

1

Sheet

Complete if Known							
Application Number	10/590,424						
Filing Date	08/23/06						
First Named Inventor	John Babish						
Art Unit							
Examiner Name							
Docket Number	068911-0160	_					

EXAMINER'S INITIALS	CITE NO.		Document Number nber-Kind Code2 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	A1	US	3,552,975	01/5/1971	Worden,et al.	
	A2	US	3,720,517	03/13/1973	Bavisotto, et al.	
	A3	US	3,932,603	06/13/1976	Haas	
	A4	US	3,933,919	01/20/1976	Wilkinson	
	A5	US	3,965,188	06/22/1976	Westermann, et al.	
	A6	US	4,123,561	10/31/1978	Grant	.41
	A7	US	4,133,903	01/09/1979	Thiele, et al.	
	A8	US	4,148,873	04/10/1979	Owades	
· · · · · · · · · · · · · · · · · · ·	A9	US	4,154,865	05/15/1979	Grant	
	A10	US	4,389,421	06/21/1983	Palamand	
	A11	US	4,170,638	10/09/1979	Owades	
	A12	US	4,401,684	08/30/1983	Versluys	
	A13	us	4,473,551	09/25/1984	Schinitsky	
	A14	US	4,554,170	11/19/1985	Panzer, et al.	
	A15	US	4,644,084	02/17/1987	Cowles, et al.	1
	A16	US	4,692,280	09/08/1987	Spinelli	
	A17	US	4,767,640	08/30/1998	Goldstein, et al.	
	A18	us	4,857,554	08/15/1989	Kallimanis	
	A19	US	5,006,337	04/09/1991	Motitschke, et al.	
	A20	US	5,013,571	05/07/1991	Hay	
	A21	US	5,041,300	08/20/1991	Todd et al.	
	A22	US	5,073,396	12/17/1991	Todd, Jr.	
	A23	US	5,082,975	01/21/1992	Todd, Jr., et al.	
	A24	US	5,155,276	10/13/1992	Paul	
	A25	US	5,166,449	11/24/1992	Todd, Jr., et al.	
	A26	US	5,286,506	02/15/1994	Millis, et al.	_
	A27	US	5,296,637	02/012000	Ting, et al.	
	A28	US	5,387,425	02/07/1995	Hsu, et al.	
	A29	US	5,604,263	02/18/1987	Tobe, et al.	
	A30	US	5,624,236	11/23/1993	Ogasahara, et al.	
	A31	US	5,641,517	06/24/1997	Eskeland, et al.	
	A32	US	5,827,895	10/27/1998	Nutter, et al.	
	A33	US	5,968,539	10/19/1999	Beerse et al.	
		EX	AMINER		DATE CONSIDERED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for form 1	449/PTO)			Complete if Known				
					Α	pplication Number	10/	10/590,424	
		DISC	LOSURE STA	IEMENI	F	ling Date	08/23/06		
BY APPLI					First Named Inventor Art Unit		Johi	n Babish	
Use as many s	ineets as	neces	ssary)						
						xaminer Name			
214			- f	7		ocket Number	0690	911-0160	
Sheet	2		of	7	L		060		
			U.S. PATE	ENT DOC	UN	MENTS CONT.			
EXAMINER'S INITIALS	CITE NO.		Document Number nber-Kind Code2 (# known)	Publication Dat MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
	A34	US	5,919,813	07-06-199	9	De Jua	an		
	A35	US	6,020,019	05/21/200	2	Ting et	al.		
	A36	US	6,129,907	02/01/200	0	Sreenivasa	n, et al.		
	A37	US	6,200,594	03/13/200		Ernest e			
	A38	US	6,383,527	05/07/200		Artman, et al.			
=	A39	US	6,391,346	05/21/200	2	Newmark,	et al.		
	A40	US	6,440,465	08/27/200		Meisn			
	A41	US	6,447,762	09/10/200	_	Galce			
	A42	US	6,583,322	06/24/200		Shalai, e			
	A43	US	6,689,388	02/10/2004		Kuhrt			
	A44	US	6,790,459	09/00/2004		Cheng, e	et al.		
	A44	US	6,801,860	10/05/200		Dessen e			
	A45	US	7,279,185	10/29/2007 06/20/2002		Babish, e	et al.		
	A46	US	20020076452			Babish, e			
	A47	US	20020077299	06/20/200		Babish, e			
	A48	US	20020086062	07/04/200		Kuhrt			
	A49	US	20020086070	07/04/200		Kuhrt			
	A50	US	20020028852	03/07/200	2	Ghai, e	t al.		
•	A51	US	20030077313	04/24/200		Schwartz, Rob		•	
	A52	US	20030096027	05/22/200		Babish, e			
	A53	US	20030113393	06/19/200		Babish,			
	A54	US	20030133958	07/17/200		Kuno, e			
	A55	US	20030180402	09-25-200		Jia et			
	A56	US	20040072900	04/15/200		Artman e		<u> </u>	
	A57	US	20040086580	05/06/200		Tripp, e		_	
	A58	US	20040137096	07/15/200		Kuhrt		-	
	A59	US	20040219240	11/04/200		Babish, e			
	A60	US	20040151792	08/00/2004		Tripp, et al.			
	A61	US	20040138199	07/00/200	4	Gogliotti,	et al.		
	T								
		EX	AMINER			DAT	E CONSIDERE	D	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for form 1449/PTO							Complete if Known					
						A	Application Number	10/590,424	4			
			DISCLOSURE	STA	TEMENT	F	iling Date	08/23/06				
BY AF						F	irst Named Inventor	John Babis	h			
(USE as I	many sn	eets as	necessary)			A	Art Unit					
						Examiner Name						
Sheet	T	3	of	Т	7	4-	Oocket Number	068911-016	60			
Oncor				DEIGN			DOCUMENTS					
EVANIA	icos 1					_	Name of Patentee or	Pages, Columns, Lines	Tropo	lation		
EXAMINER'S INITIALS		CITE NO.	Foreign Patent Document Country Codes -Number 4-Kind Codes (if known)		Publication Date MM-DD-YYYY		Applicant of Cited Documen					
									Yes	No		
		B1	DE 198416		03/16/2000		Mueller	Abstract				
		B2	DE 221214	8	09/28/1972		GEN FOODS CORP	Abstract	 			
		В3	DE 393114	7	03/28/1991	1	SOLONG NATURAL LTD	Abstract				
		В4	JP 0719435	51	08/01/1995	5	Nippon Zoki Pharm Co., Ltd.	Abstract				
		В5	JP 410025247		01/27/1998		ASAHI BREWERIES LTD	Abstract				
		B6	JP 10152428		06/09/1998		KANEBO LTD	Abstract				
		B7	JP 906724		03/11/1997		Ashai Breweries, Ltd	Abstract				
		B8	JP 04202138		07/22/1992		Asahi Breweries Ltd	Abstract				
		В9	JP 6312924		11/08/1994	4	Asahi Breweries Ltd	Abstract				
_		B10	JP 3632112	19	09/02/1988	3	TAIYO KORYO KK	Abstract				
		B11	JP 807336	9	03/19/1996	_	Kubo M			ļ		
		B12	RU 204595	5	10/20/1995	5_	Nikitina	Abstract				
		B13	SU 124701	1	07/30/1986	3	SP K B KHIM N PROIZV OBEDINEN	Abstract				
		B14	WO 00/683	11/16/2000		Yakima Chief, Inc.						
		B15	WO00/74696		12/14/2000	0	OXFORD NATURAL PRODUCTS PLC					
		B16	WO02/02582		01/10/2002		Deutsches					
		B17	WO99/4462		09/10/1999	_	NPS Pharmaceutical	3	<u> </u>	<u> </u>		
		B18	WO 03/08224		10/09-/003		Alcon, Inc.			Ь—		
		B19	GB 2 330 076		04/14/1999		S.S. Steiner, Inc.			 		
		B20	EP 0 606 5	99	07/20/1994	4	Miller Brewing		├─	├—		
		·				_			 	├─		
	-								 	┈		
						_			1	 		
												
			· · · · · · · · · · · · · · · · · · ·									
						_	<u> </u>					
			EXAMINER				DATI	CONSIDERED				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

	rm 1449/P	то	•	Complete if Known		
			<u>_</u>	Application Number	10/590,424	
		N DISCLOSUR		Filing Date	08/23/06	
· · · · — · ·		BY APPLICAN	Τ	First Named Inventor	John Babish	
e as mai	ny sheets	as necessary)		Art Unit		
				Examiner Name		
eet	4	of	7	Docket Number	068911-0160	
	OTH	ER ART (Inclu	ding Author, T	itle, Date, Pertine	nt Pages, Etc.)	
	C1	"Information on arth	rotrimtm product", d	ownloaded from Internet	8/30/02.	
	C2			nd PM", downloaded fror		
	C3			s", downloaded from inte	rnet 02/15/2005	
	C4		Pharmacol. Comm.			
	C5			95: 621-624 and 625-628	(2003)	
	C6		m. Soc. 545 (1959)			
	C7		m. Soc. (c):2810 (19			
	C8		n. Chem. <u>49</u> :861-86			
	C9		m. Soc. <u>73</u> :1850-185			
	C10			rch <u>60(1):</u> 138-142 (1972)	
	C11		J. Med. Chem. 38:6			
	C12		Biochem. <u>115</u> :207-2			
	C13		zyme regul <u>22</u> :27-55			
	C14		Chem. <u>252</u> :6438-64			
	C15		or. Biol. <u>35</u> :285-297 (
	C16		Pharm. Sci. 4:450-4			
	C17		I. 59:253-276 (1976		nn 200 245	
	C18			Publishing Group, Vol. 1,	pp. 309-315.	
	C19	Costa, et al. Digest	Liver Dis. 35:642-6	ing stuffs and Farm Supplies J. 11:694 (1926)		
	C20			mm. 261:218-223 (1999)		
	C21			num. 201.218-223 (1999) eumatic and Immunologic Diseases, Cleveland Clinic,		
	C22		c.org, March 14, 200			
	C23		Cutan Med. Surg. 6(5			
	C24	Germany "The Ab	solutely German Drir	nk," contents of beer, 200	04. 5 pages.	
	C25	Gerhäuser C. Fur	onean Journal of Ca	ncer 41 (2005), pp. 1941	-1954	
	C26			6:1019-1027 (2001)		
	C27	Halter, et al. Gut 49				
	C28		3io. Chem. 246:6713	3-6721 (1971)		
	C29		er Res. 51:813-819			
	C30		h Report for PCT/US			
	C31		h Report for PCT/US			
	C32		atol. 65(4):379-382 (
	C33			2(11):1789-1796 (1997)		
	C34		Res Opin. 8:145-149			
	C35		d. J. Gastroenterol. 3			
	C36		at. Prod 61:2-7 (1998			
	C37			ent 2s93-s101 (1998)		
	C38			sen schaft, 1990, 43(1), 4-16		
	C39	Pippa, et al. Scand	. J. Gastroenterol. S	uppl. 167:32-35 (1989)		
	C40	Plewig, et al. J Inve	est. Dermatol. 65(6):	532-536 (1975)		
	C41		stroenterol. Hepatol.			
				45 (4000)	 -	
	C42		Nat Prod 61:1212-12			
	C42 C43		Nat Prod 61:1212-12 semary-eco Botany,			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

	orm 1449/F	то			Complete if Known							
					Application Number	10/590,424						
			.OSURE	STATEMENT	Filing Date	08/23/06						
	PLICAN				First Named Inventor	John Babish						
lse as ma	any sheets	as necessa	ary)	•	Art Unit	001111 Babioii						
					Examiner Name							
heet	5		of	7	Docket Number	068911-0160						
	C44			Dis. 35:607-609 (20								
	C45											
	C46				0 200-000 224 /	2004)						
	C47				s. Comm. 289:220-224 (2001)						
	C48			er res. 61:6307-6312								
	C49			Pharmacol. 18:23-3		Derived From Hops, Journal of						
	C50				ts, Vol. 56, No. 2 <u>, 1998,</u>							
	C51			Cancer Res. <u>60</u> :239		pp. 02 01						
	C52			s. <u>58</u> :717-723 (1988								
	C53				n. 59(4):740-742 (1996)							
	C54					answer to arthritis, cancer &						
	001											
	C55	alzheimer's disease," hohm press (2000) release 7; pp. 147-151, 248. Tibble, et al. Drugs Today 37:85-96 (2001)										
	C56	Tibble, et al. Gut 45:362-366 (1999)										
	C57	Tobe, et al. Biosci. Biotech. Biochem 61(1):158-159 (1997)										
C58 Vanhoenacker, et al., Analysis of iso					pha-acids and reduced iso-alpha-acids in beer by direct							
		injection a	nd liquid ch	romatography with i	ultraviolet absorbance detection or with mass							
				al of Chromatography, Vol. 1035, No.1, (4-30-2004), pp.53-61								
	C59_				dicine <u>27</u> :612-616 (1999)							
	C60	Warner, e	t al. Proc N	atl Acad Sci USA <u>96</u>	<u>6</u> :7563-7568 (1999) ins & Other Lipid Mediators <u>59:</u> 1-235 (1999)							
	C61											
	C62			tters <u>465</u> :103-106 (2								
	C63	Yui, et al. Biol. Pharm. Bull. 26:753-760 (2003)										
	C64				Report for EP Application No. 05723895.8 (5 pages)							
	C65	International Search Report for related PCT Application No. PCT/US06/30920										
	C66	Gilani, A.H., Phytotherapy Research, 13 (1999), pp. 665-669										
	C67	International Search Report for related PCT Application No.: PCT/US06/47196 Kaltner, Investigation of Formation of Hops Aroma and Technological Measures for Production of										
	C68	Kaltner, In	vestigation	of Formation of Hop	os Aroma and Technolog	lical Measures for Production of						
					ty of Munich, Approved							
	C69			t, November 2007,		Hops and Beer: To your Good						
	C70	Ward et a	l Therane	utic Potential of Pho	sphoinositide 3-Kinase I	nhibitors, Chemistry & Biology,						
	1 670	Vol 10 2	07-213, Ma	rch 2003	opriolitocitido o randoo i							
	C71	Arner, P.,	Insulin Res	sistance in Type 2 D	iabetes - Role of the Ad	ipokines. Curr. Mol. Med.;						
	"	Arner, P., Insulin Resistance in Type 2 Diabetes — Role of the Adipokines. Curr. Mol. Med.; 5(3):333-339, (May 2005).										
	C72	Berenbaum, M.C., What is Synergy?: Pharmacol Rev; 41(2):93-141 (1989)										
	C73	Boden, G	., Role of F	atty Acids in the Pat	hogenesis of Insulin Res	istance and NIDDM. Diabetes						
		46(1): 3-10. (1997).										
		Cho et al., Akt1/PKBa Is Required for Normal Growth but Dispensable for Maintenance Glucose Homeostasis in Mice, J Biol Chem 276:38349-38352 (2001).										
	C74	Glucose H	Cho et al., A	Akt1/PKBa Is Require is in Mice, J Biol Che	ed for Normal Growth bւ em 276:38349-38352 (20	t Dispensable for Maintenance 001).						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for t	form 1449	PTO			Complete if Known				
INFOR	BAATIO	N DIGGL OF		OTATEMENT	Application Number	10/590,424			
			UKE	STATEMENT	Filing Date	08/23/06			
	PLICA	N I 's as necessary)			First Named Inventor Art Unit	John Babish			
000 45 ///	arry street	s as necessary)							
					Examiner Name				
Sheet		6	of	7	Docket Number	068911-0160			
	C75			sistance and a Diab Science 292:1728-1		ome in Mice Lacking the Protein			
	C76	Chou	, T.C.,	et al., Quantitative A	nalysis of Dose-effect R itors; Adv Enzyme Regu	elationships; The Combined I 22:27-55, (1984).			
	C77	Jour. Med. 344	4:pp. 90	07-916, (2001).		atoid Arthritis; New England			
	C78	Receptors on	Macrop	hages; J. Exp. Med	186:1027-1039, (1997)				
	C79	Isolated Mamr	nalian I	Nuclei; Nucl Acids F	Res 11:1475-1489, (1983				
	C80	Adipocytes; Bi	iochem	Biophys Res Comn	on of Adiponectin Gene I nun, 290:1084-1089, (20	02).			
	C81	Mol Med. 74(1):1-12,	(Jan 1996).	Signal Transduction: A Model of the Cytokine System. J				
	C82	(1959).			erted Plots in Enzyme Kinetics; Nature 184:1296-1298, ne 72-kDa Protein-tyrosine Kinase Ptk72 with the B-cell 613–8619, (1992).				
	C83	Antigen Recei	otor, J.	Biol. Chem. 267:86					
	C84	244, (2003).			ident Cell Survival by Syk and Rac; Blood 101, pp. 236-				
	C85	Lipogenesis D	uring A	dipose Conversion	egulation of Stearoyl Coenzyme A Desaturase Activity and of 3T3-L1 Cells; J Biol Chem, 257:12224-12230, 1982. Regulation by PPARgamma Agonist and Constitutively, 16:1040-1048, (2002). Improve Glucose Homeostasis by Stimulating Fatty Acisis 137 Suppl:S75-S80, (1998).				
	C86	Active PPARg	amma	2; Mol. Endocrinol.,					
	C87	Uptake in the	Adipoc	ytes; Atherosclerosi					
	C88	and Phosphoi (2005).	nositide	e 3-Kinase; J. Biol. C	Chem. 280, No. 2, Issue (the Syk Protein-tyrosine Kinaso of January 14, pp. 1543–1551,			
	C89	and Enhance (2001).	Insulin-	Mediated Control of	Increase Plasma-Adipose Tissue FFA Exchange Capacit of Systemic FFA Availability; Diabetes 50(5):1158-1165, from Rabbit Skeletal Muscle; Effect of Insulin on the States of Residues in vivo; (1983) Eur. J. Biochem.				
	C90	Parker, P. J., of Phosphoryl 130:227–234.	ation of	Slycogen Synthase f f the Seven Phospho					
	C91				es Downstream Signaling Events During Human sis, J. Immunol. 163: 6785–6793, (1999)				
· · · · · ·	C92	Raz, I, et al.; I intervention in	Diabete fat trar	s: insulin resistance nsport and storage;	e and derangements in lipid metabolism. Cure Through Diabetes Metab. Res. Rev.; 21: 3-14 (2005).				
	C93	Stumvoll, M., (224, (2002).	et al., C	Glitazones: clinical e	fects and molecular med	chanisms. Ann Med 34(3): 217-			
				· · · ·					
		EXAMINE	R	·	DA	TE CONSIDERED			
			E - 11		1	through citation if not in conformance an			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Subst. for	form 1449/I	PTO		Complete if Known			
INIEGO		N DIGG! GG!!D!	- 074754547	Application Number	10/590,424		
	_	N DISCLOSUR	STATEMENT	Filing Date	08/23/06		
	PLICAN	N I s as necessary)		First Named Inventor	John Babish		
(000 00 ///	uny once	s us necessary,		Art Unit			
	_	-		Examiner Name			
Sheet		7 of	7	Docket Number	068911-0160		
	C94	van der Kraan P.M., Metab Care,3:205-2		destructive mediators in	osteoarthritis. Curr Opin Clin Nutr		
	C95	Verdu et al., Cell-au cell Biol 1:500-505 (tonomous regulation (1999).	of cell and organ growth in Drosopholia by Akt/PKB; Nat			
	C96	Opin Pharmacol. Au	g;3(4):426-434, (2003	phoinositide 3-kinase inhibitors as therapeutic agents. Curr			
	C97	oxygenase-2 are as Acad. Sci. USA 96:7	sociated with human (7563-7568, (1999).	ectivities for cyclo-oxygenase-1 rather than cyclo- gastrointestinal toxicity: A full in vitro analysis. Proc. Natl.			
	C98	Investig Drugs 13:74	13-762, 2004.		ent for allergic and autoimmune disorders. Expert Opin		
	C99		d Receptor Alpha and	cids Derived From Hops, Activate Both Peroxisome d Gamma and Reduce Insulin Resistance. J Biol Chem,			
	C100				eptor with protein-tyrosine kinase. Biochem. 213: 455–459, (1993).		
	 C101 Yamauchi, T., et al., The mechanisms by Which Both Heterozygous Peroxisome Proliferator-activated Receptor gamma (PPARgamma) Deficiency and PPARgamma Agonist Improve Insuli Resistance; J Biol Chem 276(44): 41245-41254, (2001). C102 Yang, W. S., et al., Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin; J Clin Endocrinol Metab 86(8): 3815-3819, (2001). 						
	C103 El-Toumy et al., Polyphenois from Acacia Nilotica Leaves and Evaluation of Antihyperglycemic Effect of Aqueous Extract, Bulletin of the Faculty of Pharmacy (2004), 42 (2), 317-325						
-	L	EXAMINER		DA	TE CONSIDERED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

BST99 1621527-1.068911.0160